Salute e Benessere

Coway Announces Financial Results for Q2 FY2023

Coway's reported earnings are as follows: Coway's reported earnings are as follows: Cumulative revenue for 2023 has now reachedKRW 1,954.5 billion(+2.5% YoY) and an operating profit ofKRW 369.8 billion(+6.1% YoY). Domestic health appliance sales revenue rose toKRW 590.4 billion(+2.9% YoY), primarily attributed to successful product sales across various categories, including water purifiers, air purifiers, and mattresses. The total overseas subsidiaries revenue for Q2...
PR Newswire
09/08/2023

Sathgen Therapeutics completes dosing of the first two cohorts of healthy…

Sathgen is a clinical-stage novel therapeutics venture focused on bringing therapies for difficult-to-treat diseases like viral infections. Their lead molecule, MSP008-22, has widespread anti-viral potential due to its ability to inhibit both viral entry and replication. This NCE has demonstrated exceptional efficacy and safety against COVID-19 in preclinical development. Sathgen is a clinical-stage novel therapeutics venture focused on bringing therapies for difficult-to-treat diseases like...
PR Newswire
09/08/2023

Rejuvenate Biomed announces publication of data showing that RJx-01…

RJx-01 is a safe, orally administered and proprietary combination drug comprised of metformin and galantamine. RJx-01 was identified by Rejuvenate Biomed's CombinAgeTM and CelegAgeTM drug discovery platforms and is being developed for sarcopenia and other age-related diseases. RJx-01 is a safe, orally administered and proprietary combination drug comprised of metformin and galantamine. RJx-01 was identified by Rejuvenate Biomed's CombinAge TMand CelegAge TMdrug discovery platforms and is...
PR Newswire
09/08/2023

STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at…

The presentation entitled "Discovery of STC-15, an orally bioavailable, highly selective METTL3 inhibitor for the treatment of AML and solid tumours: The first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development" will detail the Company's discovery efforts in optimising novel chemistries and the identification of STC-15 for evaluation in clinical studies. Details of the ongoing first-in-human clinical trial in patients with solid tumours can be…
PR Newswire
09/08/2023

Photocure ASA: Results for the second quarter and first half of 2023

Photocure reported total group revenues of NOK 144.3 million in the second quarter of 2023 (NOK 100.6 million), and an EBITDA* of NOK 23.4 million (NOK 1.4 million). Hexvix/Cysview revenues ended at NOK 115.9 million in the quarter (Q2 2022: NOK 99.9 million), and the total group revenues includes a milestone payment related to the development of Cevira by Asieris of NOK 26.9 million. The EBIT was NOK 16.8 million (NOK -4.6 million), and the cash balance at the end of the period was NOK 258.9…
PR Newswire
09/08/2023

Novozymes delivers results within expectations in the first half of 2023 and…

After the first half of 2023, Novozymes sees overall stability in a volatile environment and delivers 3% organic sales growth. Following destocking and lower consumer demand, the organic full-year sales growth outlook is slightly narrowed from 4-7% to 4-6%. Growth is expected to be driven mainly by pricing.COPENHAGEN, Denmark – August 9, 2023. Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special...
Nasdaq GlobeNewswire
09/08/2023

Interim report for 1H 2023

Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement
Nasdaq GlobeNewswire
09/08/2023

Novartis remibrutinib Phase III trials met their primary endpoints and showed…

Ad hoc announcement pursuant to Art. 53 LRThe Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across urticaria disease activity scores 1 Patients on remibrutinib saw rapid improvement as early as 2 weeks after treatment initiation 1 Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and demonstrated a favorable safety profile, including balanced liver function tests in...
Nasdaq GlobeNewswire
09/08/2023

Pharming announces first patient enrolled in Phase III clinical trial of…

Pharming's single-arm, open-label clinical trial will evaluate the safety, tolerability, and efficacy of leniolisib in three patients 12 years of age and older who have a confirmed APDS diagnosis. Each patient will receive weight-based dosing up to 70mg of leniolisib twice daily for 12 weeks. The study's primary efficacy endpoints and secondary endpoints mirror those used to evaluate the clinical outcomes in each of the leniolisib APDS trials. Pharming's single-arm, open-label clinical trial...
PR Newswire
09/08/2023

Ischemic Stroke Market is Likely to Increase at a Steady Growth Rate, Examines…

Key Takeaways from the Ischemic Stroke Market Report Key Takeaways from the Ischemic Stroke Market Report Discover which therapies are expected to grab the major ischemic stroke market share @Ischemic Stroke Market Report Ischemic Stroke Overview Ischemic stroke is a medical condition characterized by a sudden disruption of blood flow to a particular part of the brain, leading to damage or death of brain cells due to lack of oxygen and nutrients. It is the most common type...
PR Newswire
08/08/2023

Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating…

REGULATED INFORMATIONNyxoah ReportsSecond Quarterand First Half 2023Financial and OperatingResultsMont-Saint-Guibert, Belgium –August 8 , 202310:05pm CET / 4:05pmET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results...
Nasdaq GlobeNewswire
08/08/2023

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous…

NEW YORK and BERLIN, Aug.08, 2023(GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience's Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The Phase 1 open-label, 4-period crossover study assessed the safety, tolerability, and pharmacokinetic profile of 60mg, 90mg and 120mg of PCN-101 delivered...
Nasdaq GlobeNewswire
08/08/2023

Monthly information related to total number of voting rights and shares…

Monthly information related to total number of voting rights and shares composing the share capital _July 31 , 2023 .Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – FranceListing markets:Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) &Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com DateTotal of shares composing the share capital...
Nasdaq GlobeNewswire
08/08/2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2023

Aggregatedpresentationbydayandbymarket NameofissuerIdentificationcodeof issuer(Legal Entity Identifier)Day of transactionIdentificationcodeof financialinstrumentAggregated daily volume(innumber of shares)Dailyweightedaveragepriceof the purchased shares *Market(MICCode) IPSEN549300M6SGDPB4Z94P1131/07/2023FR001025915038114.60AQEUIPSEN549300M6SGDPB4Z94P1131/07/2023...
Nasdaq GlobeNewswire
08/08/2023

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II…

The primary endpoint of the Phase II is the American College of Rheumatology (ACR) 20% Response (ACR 20) rate at 12 weeks. Secondary and exploratory endpoints include ACR 50, ACR 70, numerical rating scale (NRS) for pain score, inflamed and painful joint counts, Health Assessment Questionnaire Disability Index (HAQ-DI), Routine Assessment of Patient Index Data 3 (RAPID-3), Clinical Disease Activity Index (CDAI) and safety. These endpoints reflect the expectation that Natrunix may provide...
Nasdaq GlobeNewswire
08/08/2023

IoT Medical Devices Market worth $166.5 billion | MarketsandMarkets

The market for IoT medical devices is driven by factors such as the increasing prevalence of chronic diseases, the need for efficient and cost-effective healthcare solutions, the rising adoption of telemedicine and remote patient monitoring, and advancements in sensor technology, connectivity, and data analytics. However, interoperability & transparency issues, the high setup and operational costs, and data privacy concerns in IoT medical devices market are expected to restrain market growth…
PR Newswire
08/08/2023

Transactions in connection with share buy-back program

Company announcement no. 39 - 238 August 2023 Transactions in connection with share buy-back program On 3 August 2023 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 38 - 23. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules...
Nasdaq GlobeNewswire
08/08/2023

Endoscopy Devices Market size worth $ 64.15 Billion, Globally, by 2030 at 7.3%…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=63532 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=63532 Browse in-depth TOCon" Endoscopy Devices Market " 202 - Pages 126 – Tables 37 – Figures Global Endoscopy Devices Market to Exhibit Steady Expansion: Olympus,KARL STORZ, Stryker, and Others Set to Dominate The demand for minimally invasive medical procedures will drive...
PR Newswire
08/08/2023

Breast Biopsy Devices Market worth $2.6 billion | MarketsandMarkets

The major factors driving the growth of this market include the growing prevalent cases of breast cancer, the increasing number of breast cancer screening programs, the growing demand for minimally invasive and non-invasive procedures, and the improved reimbursement scenario. The major factors driving the growth of this market include the growing prevalent cases of breast cancer, the increasing number of breast cancer screening programs, the growing demand for minimally invasive and...
PR Newswire
08/08/2023

"Confessions of a Reluctant Caregiver" Joins Forces with UK Health Radio

"Confessions of a Reluctant Caregiver" offers a candid and unfiltered platform where caregivers can openly discuss the challenges and triumphs they experience in their roles. Spearheaded by JJ, Natalie, and Emilie, three compassionate sisters, the podcast combines the power of storytelling, guest interviews, and information sharing to relate, educate, and inspire caregivers of all ages and in all situations. "Confessions of a Reluctant Caregiver" offers a candid and…
PR Newswire
08/08/2023

Oncolytics Biotech® Successfully Raises US$15 Million to Advance Breast and…

In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriter an option (the "Over-Allotment Option"), exercisable in part or in whole at the Underwriter's sole discretion, at any time beginning on the Closing until 30 days following the Closing, to purchase up to that number of additional Equity Units, Common Shares or Warrants, or any combination thereof, as is equal to 15% of the aggregate number of Equity Units sold in the Offering to cover the…
PR Newswire
08/08/2023

SPARK™ CLEAR ALIGNERS ANNOUNCES KEY CLINICAL UPDATES & DOCTOR-DRIVEN INNOVATIONS…

"Spark Approver Web is more convenient to use, resulting in time savings for orthodontists by providing flexibility to access cases anytime, whether at the office or home," said Eric Conley, President of Ormco. "This includes web-based access to the most commonly used desktop features of Spark Approver. In addition, DEXIS IOS integration optimizes Spark's open platform by creating a continuous workflow from scanning to shipment." "Spark Approver Web is more convenient to…
PR Newswire
08/08/2023

AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating…

Topline data expected as early as Q1 2024 AIM ImmunoTech Inc. (NYSE American: AIM)(“AIM”) today announced the completion of enrollment in the company's Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions (“AMP-518”). The study has met the planned enrollment of 80 AMP-518 subjects ages 18 to 60 years who have been randomized 1:1 to receive twice-weekly intravenous infusions of Ampligen or placebo for 12 weeks, with a follow-up phase of two...
Nasdaq GlobeNewswire
08/08/2023

AUSTIN BUTLER, YSL BEAUTY NEW GLOBAL AMBASSADOR

"I was honored to be asked to join the YSL Beauty family",Austin Butler says. "Over the last few years, I've spoken with people who knew M. Saint Laurent. He broke through labels. He was a rebel, and I love that about him. I feel privileged to be a part of the heritage he set in motion." "I was honored to be asked to join the YSL Beauty family",Austin Butlersays."Over the last few years, I've spoken with people who knew M. Saint Laurent. He broke through…
PR Newswire
08/08/2023
Altri  Comunicati